Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.62 |
| ▸ | FAAH | O00519 | 4/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510515 | 1.00 | MGLL (0.62) | MGLLFAAHHSP90AA1LMNATSHR | |
| SCHEMBL8530013 | 0.85 | MGLL (0.67) | MGLLFAAHHSP90AA1TDP1ALDH1A1 | |
| SCHEMBL10886262 | 0.84 | MGLL (0.60) | MGLLFAAHHSP90AA1ALDH1A1PKM | |
| SCHEMBL32670837 | 0.84 | NSD2 (0.67) | MGLLFAAHHSP90AA1POLBTDP1 | |
| SCHEMBL29510746 | 0.84 | PARP1 (0.65) | MGLLFAAHHSP90AA1LMNAALDH1A1 | |
| SCHEMBL11023896 | 0.84 | MGLL (0.64) | MGLLFAAHHSP90AA1ALDH1A1PKM | |
| SCHEMBL10515423 | 0.84 | PARP1 (0.65) | MGLLFAAHHSP90AA1LMNAALDH1A1 | |
| SCHEMBL522308 | 0.84 | NSD2 (0.67) | MGLLFAAHHSP90AA1POLBTDP1 | |
| SCHEMBL10882516 | 0.83 | MGLL (0.58) | MGLLFAAHHSP90AA1ALDH1A1PKM | |
| SCHEMBL24529797 | 0.82 | MGLL (0.62) | MGLLFAAHHSP90AA1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114432301-B | Covalent inhibitor derivative and application thereof in treatment of viral infection | 北京大学 | 2024-05-31 | — | — | CN | disclosed |
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-31 | — | — | US | disclosed |
| WO-2022160156-A1 | LIGASE FUSION PROTEINS AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-08-04 | — | — | WO | disclosed |
| CN-114432301-A | Covalent inhibitor derivative and application thereof in treating virus infection | 北京大学 | 2022-05-06 | — | — | CN | disclosed |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | URSURE, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200123261-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC | 2020-04-23 | — | — | US | disclosed |
| WO-2019075487-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | URSURE, INC. HARVARD LIFE LAB (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-2682409-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9598466-B2 | Glycopeptide constructs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-03-21 | — | — | US | disclosed |
| US-9493580-B2 | Multivalent glycopeptide constructs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-11-15 | — | — | US | disclosed |
| US-8846411-B2 | Derivatives, reagents, and immunoassay for detecting levetiracetam | MICROGENICS CORPORATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130095173-A1 | MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | disclosed |
| US-20100317024-A1 | DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM | MICROGENICS CORPORATION | 2010-12-16 | — | — | US | disclosed |
| EP-1447099-B1 | Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same | KRATZ FELIX (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1447099-A2 | Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same | Kratz, Felix (DE) | 2004-08-18 | — | — | EP | disclosed |
| EP-0934081-B1 | ANTINEOPLASTIC CONJUGATES OF ALBUMIN | KRATZ FELIX (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6709679-B2 | CONSISTING OF NATIVE OR THIOLATED TRANSFERRIN OR ALBUMIN OR OF POLYETHYLENE GLYCOL WITH ATLEAST ONE MERCAPTAN, HYDROXY OR AMINE GROUP AND CYTOSTATIC COMPOUNDS DERIVED THROUGH MALEINIMIDE OR HYDROXYSUCCINIMIDE ESTER COMPOUNDS | KRATZ FELIX (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | KRATZ FELIX (DE) | 2002-02-14 | — | — | US | disclosed |
| US-6310039-B1 | TUMOR-INHIBITING CONJUGATES OF PROTEINS AND POLYMERS CONSISTING OF A SUITABLE CARRIER SYSTEM AND CYTOSTATIC COMPOUNDS | KRATZ FELIX (DE) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123261-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | MGLL 4036/4885FAAH 4539/4885HSP90AA1 1136/4885 |
| US-20130095173-A1 | MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, GOLGA2, FUT5 | MGLL 439/4885FAAH 2540/4885HSP90AA1 1524/4885 |
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | TFRC, ALB, FOLR1 | MGLL 3432/4885FAAH 1010/4885HSP90AA1 286/4885 |
| US-20200239598-A1 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | DNTT, POLRMT, SLC29A1 | MGLL 3427/4885FAAH 3206/4885HSP90AA1 3981/4885 |
| US-20100317024-A1 | DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM | EPM2A, IGLV6-57, LAMTOR3 | MGLL 828/4885FAAH 424/4885HSP90AA1 4705/4885 |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | MGLL 2610/4885FAAH 4485/4885HSP90AA1 1142/4885 |
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CD44, DAO, FUT6 | MGLL 3283/4885FAAH 2169/4885HSP90AA1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.